Mortality in ST-Segment Elevation Myocardial Infarction With Nonobstructive Coronary Arteries and Mimickers.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
27
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
epublish
Résumé
The clinical characteristics and prognosis of patients with ST-segment elevation myocardial infarction (STEMI) with nonobstructive coronaries (MINOCA) are largely unknown. To assess differences in 5-year mortality in patients presenting with STEMI due to MINOCA and MINOCA mimickers as compared with obstructive disease. A retrospective analysis of a prospective registry-based cohort study of consecutive STEMI activations at 3 regional Midwest STEMI programs. STEMI without a culprit artery and elevated troponin levels were categorized as MINOCA (absence of coronary artery stenosis >50% and confirmed or suspected coronary artery plaque disruption, epicardial coronary spasm, or coronary embolism/thrombosis) or MINOCA mimickers (takotsubo cardiomyopathy, myocarditis, or nonischemic cardiomyopathy). Data were analyzed from March 2003 to December 2020. Adjusted Cox regression analysis was used to assess 5-year mortality risk in STEMI presenting with MINOCA and MINOCA mimickers in comparison with obstructive disease. Among 8560 consecutive patients with STEMI, mean (SD) age was 62 (14) years, 30% were female (2609 participants), and 94% were non-Hispanic White (4358 participants). The cohort included 8151 patients with STEMI due to obstructive disease (95.2%), 120 patients with MINOCA (1.4%), and 289 patients with MINOCA mimickers (3.8%). Patients were followed up for a median (IQR) of 7.1 (3.6-10.7) years. Patients with MINOCA and MINOCA mimickers were less likely to be discharged with cardiac medications compared with obstructive disease. At 5-year follow-up, mortality in STEMI presenting with obstructive disease (1228 participants [16%]) was similar to MINOCA (20 participants [18%]; χ21 = 1.1; log-rank P = .29) and MINOCA mimickers (52 participants [18%]; χ21 = 2.3; log-rank P = .13). In adjusted Cox regression analysis compared with obstructive disease, the 5-year mortality hazard risk was 1.93 times higher in MINOCA (95% CI, 1.06-3.53) and similar in MINOCA mimickers (HR, 1.08; 95% CI, 0.79-1.49). In this large multicenter cohort study of consecutive clinical patients with STEMI, presenting with MINOCA was associated with a higher risk of mortality than obstructive disease; the risk of mortality was similar in patients with MINOCA mimickers and obstructive disease. Further investigation is necessary to understand the pathophysiologic mechanisms involved in this high-risk STEMI population.
Identifiants
pubmed: 37971742
pii: 2811941
doi: 10.1001/jamanetworkopen.2023.43402
pmc: PMC10654797
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2343402Références
Eur Heart J. 2018 Jun 7;39(22):2032-2046
pubmed: 29850871
J Thromb Thrombolysis. 2019 Nov;48(4):533-538
pubmed: 31327089
Am J Med. 2020 Jan;133(1):73-83.e4
pubmed: 31260664
Eur Heart J. 2019 Jan 14;40(3):237-269
pubmed: 30165617
Eur Heart J. 2018 Jan 7;39(2):102-110
pubmed: 29029035
Circ Cardiovasc Qual Outcomes. 2021 Nov;14(11):e007880
pubmed: 34784229
Heart. 2019 Apr;105(7):524-530
pubmed: 30269079
Am J Cardiol. 2015 Jun 15;115(12):1661-6
pubmed: 25900352
J Am Heart Assoc. 2019 Jul 16;8(14):e011990
pubmed: 31284804
Circulation. 2019 Apr 30;139(18):e891-e908
pubmed: 30913893
Eur Heart J. 2017 Jan 14;38(3):143-153
pubmed: 28158518
Clin Cardiol. 2010 Jan;33(1):36-41
pubmed: 20063300
Am J Cardiol. 2014 May 15;113(10):1628-33
pubmed: 24698468
Am J Cardiol. 2013 Mar 1;111(5):643-8
pubmed: 23261001
Int J Cardiol. 2020 Feb 15;301:108-113
pubmed: 31740139
Cardiovasc Revasc Med. 2021 Feb;23:86-90
pubmed: 32883587
Circulation. 2017 Apr 18;135(16):1481-1489
pubmed: 28179398
J Am Heart Assoc. 2018 Jun 28;7(13):
pubmed: 29954744
Circulation. 2006 Apr 11;113(14):1807-16
pubmed: 16567565
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Front Cardiovasc Med. 2022 Nov 15;9:1032436
pubmed: 36457805
JACC Cardiovasc Imaging. 2021 Sep;14(9):1774-1783
pubmed: 33865778
Circulation. 2015 Mar 10;131(10):861-70
pubmed: 25587100
Kardiol Pol. 2010 Nov;68(11):1211-7
pubmed: 21108194
Circ Cardiovasc Qual Outcomes. 2017 Dec;10(12):e003443
pubmed: 29246884
J Intern Med. 2019 Apr;285(4):419-428
pubmed: 30474313
Int J Cardiol. 2008 Oct 13;129(3):394-8
pubmed: 18295912
Heart Lung Circ. 2018 Feb;27(2):165-174
pubmed: 28408093
Eur Heart J. 2020 Feb 14;41(7):870-878
pubmed: 31222249
Eur Heart J Acute Cardiovasc Care. 2021 Oct 1;10(7):813-822
pubmed: 34179954
Circulation. 2021 Feb 16;143(7):624-640
pubmed: 33191769
Int J Cardiol. 2018 Aug 1;264:12-17
pubmed: 29655952
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828